Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 483.5 DKK 2.49% Market Closed
Market Cap: 97.7B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Long-Term Debt
kr925m
CAGR 3-Years
34%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Long-Term Debt
kr373.6m
CAGR 3-Years
43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Long-Term Debt
€219.1m
CAGR 3-Years
33%
CAGR 5-Years
47%
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Long-Term Debt
kr82.7m
CAGR 3-Years
-67%
CAGR 5-Years
-29%
CAGR 10-Years
2%
F
Fluoguide AS
STO:FLUO
Long-Term Debt
kr623k
CAGR 3-Years
122%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Long-Term Debt
kr3.5m
CAGR 3-Years
-23%
CAGR 5-Years
24%
CAGR 10-Years
43%
No Stocks Found

Genmab A/S
Glance View

Market Cap
94.2B DKK
Industry
Biotechnology

Genmab A/S is a cutting-edge biotechnology company based in Denmark, renowned for its pioneering approach to developing differentiated antibody therapies for the treatment of cancer. Founded in 1999, the company focuses on harnessing the power of the immune system to combat various malignancies. Its flagship product, Darzalex (daratumumab), has transformed treatment protocols for multiple myeloma, achieving robust sales and establishing Genmab as a formidable player in the oncology landscape. The company's innovative platform combines proprietary technologies and skilled teams to create next-generation therapies, underscoring its commitment to improving patients' lives through targeted and effective cancer treatment solutions. As Genmab continues to build on its success, it is also expanding its pipeline with a diverse array of promising assets in various stages of clinical development. Not only does this validate its research capabilities, but it also positions Genmab for substantial future growth. The company's strategic collaborations with major pharmaceutical partners, such as Johnson & Johnson, further amplify its reach and resource capabilities, fostering a collaborative approach to accelerate drug development. With a solid financial standing and a focus on sustained innovation, Genmab A/S presents an intriguing investment opportunity for those looking to tap into the evolving landscape of biotechnology and oncology therapeutics.

GMAB Intrinsic Value
2 507.16 DKK
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Genmab A/S's Long-Term Debt?
Long-Term Debt
925m DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Long-Term Debt amounts to 925m DKK.

What is Genmab A/S's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
42%

Over the last year, the Long-Term Debt growth was 28%. The average annual Long-Term Debt growth rates for Genmab A/S have been 34% over the past three years , 42% over the past five years .

Back to Top